Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease IN RESPONSE

被引：1
|
作者：
Schechter, Meir [1 ,2 ,3 ]
Chertow, Glenn M. [4 ,5 ]
Heerspink, Hiddo J. L. [1 ,6 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[2] Hadassah Med Ctr, Diabet Unit, Dept Endocrinol & Metab, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[4] Stanford Univ, Dept Med, Sch Med, Stanford, CA USA
[5] Stanford Univ, Dept Epidemiol & Populat Hlth, Sch Med, Stanford, CA USA
[6] George Inst Global Hlth, Sydney, NSW, Australia
来源：
ANNALS OF INTERNAL MEDICINE | 2023年 / 176卷 / 07期
关键词：
D O I：
10.7326/L23-0070
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan
    Kodera, Satoshi
    Morita, Hiroyuki
    Nishi, Hiroshi
    Takeda, Norifumi
    Ando, Jiro
    Komuro, Issei
    [J]. CIRCULATION JOURNAL, 2022, 86 (12) : 2021 - +
  • [42] Dapagliflozin: reduced diabetes incidence in chronic kidney disease? Comments
    Schwarz, Peter
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2022, 17 (02) : 113 - 114
  • [43] Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
    Akihiko Koshino
    Brendon L. Neuen
    Niels Jongs
    Carol Pollock
    Peter J. Greasley
    Eva-Marie Andersson
    Ann Hammarstedt
    Cecilia Karlsson
    Anna Maria Langkilde
    Takashi Wada
    Hiddo J.L. Heerspink
    [J]. Cardiovascular Diabetology, 22
  • [44] Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
    Koshino, Akihiko
    Neuen, Brendon L.
    Jongs, Niels
    Pollock, Carol
    Greasley, Peter J.
    Andersson, Eva-Marie
    Hammarstedt, Ann
    Karlsson, Cecilia
    Langkilde, Anna Maria
    Wada, Takashi
    Heerspink, Hiddo J. L.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [45] Effects of Statins in Patients with Chronic Kidney Disease
    Ge, L.
    [J]. CARDIOLOGY, 2009, 114 : 139 - 140
  • [46] Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
    Lin, Yi-Hsuan
    Huang, Yu-Yao
    Hsieh, Sheng-Hwu
    Sun, Jui-Hung
    Chen, Szu-Tah
    Lin, Chia-Hung
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [47] The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis
    McEwan, Phil
    Gabb, Peter D.
    Davis, Jason A.
    Sanchez, Juan Jose Garcia
    Sjostrom, C. David
    Barone, Salvatore
    Kashioulis, Pavlos
    Ouwens, Mario
    Cassimaty, Syd
    Correa-Rotter, Ricardo
    Rossing, Peter
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024,
  • [48] Use of dapagliflozin in patients with advanced diabetic kidney disease
    Park, Hyun Sun
    Jung, Youn Joo
    Lee, Dong-Young
    Moon, Kyoung Hyoub
    Kim, Beom
    Kim, Hae Won
    [J]. KIDNEY RESEARCH AND CLINICAL PRACTICE, 2018, 37 (03) : 292 - 297
  • [49] THE RELATIONSHIP BETWEEN SEVERITY OF CHRONIC KIDNEY DISEASE AND HOSPITALIZATIONS IN PATIENTS WITH TYPE 2 DIABETES
    Lage, M. J.
    Boye, K. S.
    Paczkowski, R.
    Curtis, B.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A155 - A155
  • [50] Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus
    Penland, Robert C.
    Melin, Johanna
    Boulton, David W.
    Tang, Weifeng
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (05): : 551 - 559
12345